References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2014-2-41-47

mrj-549

Research Article

ЛЕКЦИИ

LECTURES

Клиническое значение лабораторных нарушений при системной красной волчанке

Clinical significance of laboratory errors in patients with systemic lupus erythematosus

Клюквина

Н.Г.

Klyukvina

N.G.

1@ru.ru

Кафедра ревматологии Института профессионального образования ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, Москва, РоссияРоссияDivision of Rheumatology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation,Russian Federation

2014

08052014

824147

2014

Клюквина Н.

Klyukvina N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/549

Лабораторное обследование является неотъемлемым компонентом ведения больных СКВ. Ряд лабораторных тестов необходим для верификации диагноза, некоторые показатели отражают развитие сопутствующей патологии (присоединение коморбидных состояний и осложнения лекарственной терапии). Мониторинг отдельных лабораторных тестов позволяет оценить эффективность терапии, а в ряде случаев свидетельствует о необходимости ее усиления. Кроме того, отдельные параметры считаются прогностическими факторами исхода заболевания. В статье приведены данные о спектре и частоте лабораторных нарушений при системной красной волчанке (СКВ). Обсуждено место лабораторных тестов в диагностике и оценке прогноза заболевания. Рассмотрена ассоциация клинических и лабораторных проявлений, возможные механизмы развития лабораторных отклонений. При- ведены международные рекомендации по мониторингу больных СКВ. Правильные объем обследования больных СКВ и трактовка полученных результатов позволяют своевременно (а иногда уже в ран- ней стадии) поставить диагноз, избежать гипердиагностики, вовремя назначить адекватную терапию и предотвратить ее ос- ложнения.

Laboratory examination is an integral part of managing patients with systemic lupus erythematosus (SLE). A number of laboratory tests need to be conducted to verify the diagnosis; some indicators attest to the development of a concomitant pathology (development of comorbid conditions and therapeutic aggravation). The monitoring of individual laboratory tests makes it possible to assess the effectiveness of therapy or indicates that it needs to be enhanced in some cases. Furthermore, some parameters are considered to be prognostic factors of treatment outcome. The article reports on the range and frequency of laboratory errors in SLE patients. The role of laboratory tests in diagnosis and assessment of disease prognosis is discussed. The relationship between clinical and laboratory manifestations and the mechanisms for preventing laboratory errors are studied. The international guidelines for monitoring SLE patients are presented. Proper range of examination of SLE patients and interpretation of the results ensures timely diagnosis (sometimes at the early stage) and allows one to avoid a hyperdiagnosis, to timely prescribe adequate therapy, and prevent its complications.

системная красная волчанкааутоантителалабораторные нарушениямониторинг больных системной красной волчанкой.

References1

Насонов ЕЛ, Александрова ЕН. Современные технологии и перспективы лабораторной диагностики ревматических заболевания. Терапевтический архив. 2010;82(5):5–9. [Nasonov EL, Aleksandrova EN. Rheumatic diseases: Current technologies and perspectives of laboratory diagnosis. Terapevticheskii arkhiv. 2010;82(5):5–9. (In Russ.)]

Александрова ЕН, Новиков АА. Лабораторная диагностика ревматических заболеваний. В кн.: Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. 2-е изд. Москва: ГЭОТАР-Медиа; 2010. С. 19–76. [Alexandrova EN,

Novikov AA. Laboratory diagnostics of rheumatic diseases. In: Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical rekomendations]. Ed. by Nasonov EL. 2st ed. Moscow: GEOTAR-Media; 2010. P. 19–76.]

Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные стандарты лабораторной диагностики ревматических заболеваний. 2 изд. Москва; 2012. С. 1–61. [Aleksandrova EN, Novikov AA, Nasonov EL. Sovremennye standarty laboratornoi diagnostiki revmaticheskikh zabolevanii [Modern standards of laboratory diagnostics of rheumatic diseases]. 2st ed. Moscow; 2012. P. 1–61.]

Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7. DOI: http://dx.doi.org/10.1002/art.1780251101.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: http://dx.doi.org/10.1002/art.1780400928.

Petri M, Orbai A-M, Alarcon G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. DOI: http://dx.doi.org/10.1002/art.34473.

Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 2010;69(9):1603–11. DOI: 10.1136/ard.2010.135186.

Arbuckle MR, James JA, Kohlhase KF, et al. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol. 2001;54(1–2):211–9. DOI: http://dx.doi.org/10.1046/j.1365-3083.2001.00959.x.

Smith MF, Hiepe F, Dorner T, Burmester G. Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(6):255–61. DOI: 10.1186/ar2834. Epub 2009 Nov 19.

Harley JB, Sestak AL, Willis LG, et al. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum. 1989;32(7):826–36.

Sherer Y, Gorstein A, Frinzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34(2):501–37. DOI: http://dx.doi.org/10.1016/ j.semarthrit.2004.07.002.

Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные стандарты лабораторной диагностики ревматических заболеваний и их применение в реальной клинической практике. Научно-практическая ревматология. 2013;51(4):368–76. [Aleksandrova EN, Novikov AA, Nasonov EL. The current standards for laboratory diagnosis of rheumatic diseases and their use in real clinical practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(4):368–76. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/1995-4484-2013-1246.

Gill MJ, Quisel AM, Rocca P, Walters DT. Diagnosis of systemic lupus erythematosus. Am Fam Physician. 2003;68(11):2179–86.

Dipti TR, Azam MS, Sattar MH, Rahman SA. Detection of anti-nuclear antibody by immunofluorescence assay and enzyme immunoassay in childhood systemic lupus erythematosus: experience from Bangladesh. Int J Rheum Dis. 2012;15(1):121–5. DOI: 10.1111/j.1756-185X.2011.01694.x. Epub 2011 Nov 30.

Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434–44. DOI: http://dx.doi.org/10.1002/art.10561.

Sjowall C, Sturm M, Dahle C, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheum. 2008;35(10):1994–2000. Epub 2008 Sep 1.

Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008;10(5):218. DOI: 10.1186/ar2488. Epub 2008 Oct 10.

Isenberg D. Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus. Lupus. 2004;13(11):881–5. DOI: http://dx.doi.org/10.1191/0961203304lu2028oa.

Bertsias G, Ioannidis J, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–82. DOI: 10.1136/ard.2010.130476. Epub 2010 Aug 19.

Попкова ТВ, Лисицына ТА. Рекомендации по ведению больных системной красной волчанкой в клинической практике (по материалам рекомендаций Европейской антиревматической лиги – EULAR). Современная ревматология. 2011;(1):4–12. [Popkova TV, Lisitsyna TA. Rekomendatsii po vedeniyu bol'nykh sistemnoy krasnoy volchankoy v klinicheskoy praktike (po materialam rekomendatsiy Evropeyskoy antirevmaticheskoy ligi – EULAR). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011;(1):4–12. (In Russ.)]. DOI: http://dx.doi.org/ 10.14412/1996-7012-2011-645.

Madison PJ, Mogavero H, Reichin M. Pattern of clinical disease associated with antibodies to nuclear riboprotein. J Rheum. 1978;5(4):407–11.

Hichon CA, Peschken CA. Sm antibodies increase risk of death in systemic lupus erythematosus. Lupus. 2007;16(3):186–94.

Насонов Е. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov E. Antifosfolipidnyi sindrom [Antifosfolipidny syndrome]. Moscow: Litterra; 2004. 440 p.]

Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2350–7. DOI: http://dx.doi.org/10.1002/1529-0131(200110)44:10%3C2350::AID-ART398%3E3.0.CO;2-A.

Manson JJ, Ma A, Rogers P, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alfa-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther. 2009;11(5):R154. DOI: 10.1186/ar2831.

Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006;55(6):900–4. DOI: http://dx.doi.org/10.1002/art.22356.

Sinico RA, Radice A, Ikehata M, et al. Anti-C1q autoantibodies in lupus nephritis. Prevalence and clinical significance. Ann NY Acad Sci. 2005;1050:193–200. DOI: http://dx.doi.org/10.1196/annals.1313.020.

Meyer OC, Nicaise-Roland P, Cadoudal N, et al. Anti-G1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther. 2009;11(3):R87. DOI: 10.1186/ar2725. Epub 2009 Jun 10.

Цанян МЭ, Александрова ЕН, Соловьев СК, Насонов ЕЛ. Антитела к С1q при системной красной волчанке – биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза. Научно-практическая ревматология. 2013;51(1):71–5. [Tsanyan ME, Aleksandrova EN, Solovyev SK, Nasonov EL. Anti-C1q antibodies in systemic lupus erythematosus are a biological marker of the activity of nephritis, a predictor for its development and a poor life prognosis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(1):71–5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-1205.

Hepbum AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford). 2010;49(12):2243–54. DOI: 10.1093/ rheumatology/keq269. Epub 2010 Sep 7.

Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: From pathophysiology to clinical

assessment. Ann Rheum Dis. 2006;65(2):144–8. DOI: http://dx.doi.org/10.1136/ard.2005.041673. Epub 2005 Aug 3.

Schur PH. Laboratory evaluation of patients with systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus, 5th ed. 2011. P. 629–54. DOI: http://dx.doi.org/10.1016/B978-0-12-374994-9.10034-8.

Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated throm-bocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006;45(7):851–4. DOI: http://dx.doi.org/10.1093/rheumatology/kel0 10. Epub 2006 Jan 17.

Vila LM, Alarcon GS, McGwin JrG, et al. Reveille, Systemic lupus erythematosus in a multiethnic U.S. cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006;55:799–806. DOI: http://dx.doi.org/10.1002/art.22224.

NgWL,ChuCM,WuAK,etal. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM. 2006 Jan;99(1):37–47. DOI: http://dx.doi.org/10.1093/qjmed/hci155.

Dvorkina O, Ginzler EM. Corticosteroid and nonsteroid anti-inflammatory drug use in systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus. 5th ed. 2011. P. 1045–60. DOI: http://dx.doi.org/ 10.1016/B978-0-12-374994-9.10056-7.

Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus ery-thematosus. Medicine (Baltimore). 2006;85(3):147–56. DOI: http://dx.doi.org/10.1097/01. md.0000224709.70133.f7.

Murakami M, Tsubata T, Shinkura R, et al. Acute lupus hemophagocytic syndrome: report of a case. Nefrologia. 2010;30(2):247–51.

Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257–63. DOI: 10.1177/0961203308100481.

Batnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein on systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005;14(8):576–82. DOI: http://dx.doi.org/ 10.1191/0961203305lu2157oa.

Williams RC, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheum. 2005;32(3):454–61.

The authors declare that there are no conflicts of interest present.